24-Dec-2025
Adaptive Biotechnologies is the top performing life sciences tools and services stock YTD
Seeking Alpha News (Tue, 23-Dec 12:06 AM ET)
Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
Globe Newswire (Thu, 18-Dec 7:30 AM ET)
Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows
Globe Newswire (Tue, 16-Dec 7:30 AM ET)
Repligen Corporation to Present at Evercore Healthcare Conference
Globe Newswire (Wed, 26-Nov 7:30 AM ET)
Repligen Corporation to Present at Upcoming November Conferences
Globe Newswire (Tue, 4-Nov 7:30 AM ET)
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Globe Newswire (Tue, 28-Oct 7:30 AM ET)
Repligen to Report Third Quarter 2025 Financial Results
Globe Newswire (Wed, 15-Oct 7:30 AM ET)
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Repligen trades on the NASDAQ stock market under the symbol RGEN.
As of December 24, 2025, RGEN stock price declined to $165.66 with 225,249 million shares trading.
RGEN has a beta of 1.31, meaning it tends to be more sensitive to market movements. RGEN has a correlation of 0.21 to the broad based SPY ETF.
RGEN has a market cap of $9.32 billion. This is considered a Mid Cap stock.
Last quarter Repligen reported $189 million in Revenue and $.46 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.04.
In the last 3 years, RGEN traded as high as $211.13 and as low as $102.97.
The top ETF exchange traded funds that RGEN belongs to (by Net Assets): VTI, IJH, VB, VBK, VXF.
RGEN has underperformed the market in the last year with a return of +13.7%, while SPY returned +17.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in RGEN shares. However, RGEN has outperformed the market in the last 3 month and 2 week periods, returning +33.7% and +3.1%, while SPY returned +4.4% and +1.4%, respectively. This indicates RGEN has been having a stronger performance recently.
RGEN support price is $163.11 and resistance is $169.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGEN shares will trade within this expected range on the day.